AstraZeneca’s big MYSTIC trial ends a complete failure as Imfinzi/tremelimumab combo flops on overall survival
Last year, AstraZeneca preached patience after initial data showed its checkpoint inhibitor Imfinzi combined with their in-house CTLA-4 drug failed to meet the primary endpoint of progression-free survival in a pivotal lung cancer trial. On Friday, that faith proved in vain as the immunotherapy also failed to improve overall survival in the keenly watched MYSTIC trial.
The trial tested Imfinzi both as a monotherapy and in combination with another checkpoint inhibitor, tremelimumab, against chemotherapy in treatment-naive patients with stage IV non-small cell lung cancer (NSCLC), a crucial arena in the battle for checkpoint drug dominance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.